Mass Tort brief
Teva's Legacy Liabilities and Paracetamol Risks
An appeals court revives prenatal Tylenol litigation while Teva faces escalating generic antitrust and medical device liabilities.
Mass Tort
Taro and Sun's $533 million price-fixing settlement established a key financial benchmark — Teva now faces clearer, highly expensive boundaries for resolving its own massive generic price-fixing liabilities.
BackgroundThe massive multidistrict litigation (MDL No. 2724) accuses multiple generic drugmakers of dividing markets and artificially inflating prices. The settlement pool includes a $200 million payment from Sun Pharmaceuticals and its subsidiary Taro, which operates major manufacturing and R&D facilities in Haifa.
- The settlement allows consumers who purchased eligible generic prescription drugs between 2009 and 2019 to submit claims until November 9, 2026, to recover inflated costs.
- The current $533 million resolution is led by Sandoz's $275 million payout and Sun's $200 million portion, providing immediate financial relief to end-payers.
- Israeli investors are monitoring Taro's payouts closely to estimate Teva's eventual financial exposure, as Teva remains a central co-defendant in the unresolved direct-purchaser litigation tracks.
Mass Tort
By narrowing judges' power to screen out expert science, the court handed 500 plaintiffs their leverage back — Kenvue and its distributors now face jury trials and severe settlement pressure.
BackgroundThis multidistrict litigation represents a massive consolidation of claims alleging that paracetamol exposure during pregnancy causes developmental disorders in children. A lower court had previously blocked the lawsuits after ruling that the plaintiffs' medical experts lacked reliable scientific methodology.
- The appellate panel ruled that the district judge overstepped her legal gatekeeping role, reinstating three key medical experts and paving the way for a high-stakes jury trial.
- In Israel, paracetamol dominates the local painkiller market through Teva's Acamol and Dexcel's Dexamol brands, making any shift in safety consensus highly consequential for local healthcare.
- Local pediatric safety regulators regularly mirror US Food and Drug Administration safety updates, meaning the revived litigation could eventually trigger warning label modifications in Israeli pharmacies.
Mass Tort
Mounting injury lawsuits over the Paragard contraceptive device continue to drain Teva's resources — the unresolved litigation prevents the company from fully closing the book on its legacy liabilities.
BackgroundTeva developed and marketed the hormone-free copper intrauterine device before selling the product line to CooperSurgical for $1.1 billion in 2017. Because Teva owned the device during its design and early distribution phases, it remains the primary defendant.
- The federal multidistrict litigation has grown to encompass more than 4,000 active lawsuits alleging that migrating plastic fragments caused severe internal injuries and required surgical removal.
- While Teva secured a defense verdict in the first bellwether trial, subsequent trials have been delayed until late 2026, prolonging the company's litigation expenses.
- Local Tel Aviv analysts view the mounting defense costs and prospective settlement payouts as a lingering drag on Teva's balance sheet and cash flow recovery.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.